Effect of High-Dose Subcutaneous Spesolimab on Skin Manifestations: Results from the Pivotal Effisayil 2 Trial of Flare Prevention in Generalized Pustular Psoriasis

Main Article Content

Bruce Strober
Matthias Augustin
Yayoi Tada
Amit Garg
Denis Jullien
Alice Gottlieb
Johann Gudjonsson
Na Hu
Patrick Hofmann
Christian Thoma
Angelo Marzano


Effisayil 2, Spesolimab, Generalized Pustular Psoriasis, Flare


Introduction & Objectives: Generalized pustular psoriasis (GPP) is a chronic, rare and potentially life-threatening skin disease, characterized by flares of sterile pustules. Spesolimab, an anti-interleukin-36 receptor monoclonal antibody, is an effective and approved treatment for GPP flares in adults. Effisayil 2 (NCT04399837) was a pivotal, randomized controlled trial that evaluated the efficacy and safety of subcutaneous spesolimab in preventing GPP flares. Here, we report the effect of high-dose spesolimab versus placebo on GPP lesions.

Materials & Methods: Eligible patients with a history of GPP were randomized (1:1:1:1) to receive one of three subcutaneous spesolimab regimens or placebo for 48 weeks. High-dose spesolimab regimen was loading dose 600 mg, followed by maintenance dose 300 mg every 4 weeks. GPP Physician Global Assessment (GPPGA) subscores for erythema, pustules and scaling/crusting, and total score were compared between high-dose spesolimab and placebo groups at baseline and over the treatment period (scale: 0, clear to 4, severe).

Results: Proportion of patients with baseline score of 0 for each GPPGA subscore and total score was generally similar between treatment groups, except erythema; (high-dose spesolimab [n=30] vs placebo [n=31]: erythema, 13.3% vs 22.6%; pustules, 66.7% vs 67.7%; scaling/crusting, 23.3% vs 22.6%; total score, 10.0% vs 12.9%). By Week 4, proportion of patients with scores of 0 increased with high-dose spesolimab versus placebo, (erythema, 33.3% vs 19.4%; pustules, 80.0% vs 41.9%; scaling/crusting, 30.0% vs 19.4%; total score, 26.7% vs 16.1%), and high-dose spesolimab group had fewer flares (10.0% vs 35.5%). This trend was maintained at Week 24 (erythema, 36.7% vs 22.6%; pustules, 63.3% vs 45.2%; scaling/crusting, 36.7% vs 19.4%; total score, 33.3% vs 19.4%) and Week 48 (erythema, 36.7% vs 22.6%; pustules, 66.7% vs 45.2%; scaling/crusting, 43.3% vs 25.8%; total score, 36.7% vs 22.6%). There were no new flares after Week 4 in high-dose spesolimab group; however, flares increased with placebo (45.2% at Week 24; 51.6% at Week 48).

Conclusion: Versus placebo, high-dose subcutaneous spesolimab resulted in a greater proportion of patients maintaining GPPGA scores of 0, a lower proportion having flares at Week 4, and no new flares after Week 4. This was sustained at Weeks 24 and 48. 


1. Choon S, et al. Am J Clin Dermatol 2022;23(Suppl 1):S21–S29

2. Burden AD, et al. Am J Clin Dermatol 2022;23(Suppl 1):S39–S50

3. Krueger J, et al. Am J Clin Dermatol 2022;23(Suppl 1):S51–S64

4. Strober B, et al. Dermatol Ther 2021;11:529–541

5. Bachelez H, et al. N Engl J Med 2021;385:2431–2440
6. SPEVIGO® prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf (accessed 29 Sept 2023)

7. Spevigo® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/spevigo-epar-productinformation_en.pdf (accessed 4 July 2023)

8. Morita A, et al. Derm Ther 2023;13:347–359;13

9. Burden AD, et al. Br J Dermatol 2023;189:138–140

10. Morita et al. Lancet 2023 Sep 19. Epub ahead of print.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>